This week's roundup of Houston innovators includes Emmanuel Urquieta of TRISH, Ariel Jones of Qualtrics XM, and Lawson Gow of Pokatok. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space health research to sports tech — recently making headlines in Houston innovation.


Dr. Emmanuel Urquieta, chief medical officer of TRISH

Emmanuel Urquieta, chief medical officer of TRISH, joins the Houston Innovators Podcast. Photo via LinkedIn

Since 2021, the Translational Research Institute for Space Health has conducted its research on four missions — which has meant an unparalleled access to space health data for TRISH.

“We really saw the value of implementing research in civilians because they are different from your traditional government astronaut,” Dr. Emmanuel Urquieta, chief medical officer for TRISH, says on the Houston Innovators Podcast. “In civilians, you see a more diverse population.”

Urquieta says TRISH's experiments on these missions all fall within a few pillars of space health, including space's effects on sensory motor skills, like balance and motion sickness, as well as mental health, environmental data from the vehicles, vital monitoring, and more. Read more.

Ariel Jones, head of health care provider solution strategy for Qualtrics XM

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe. Photo courtesy

In a guest column for InnovationMap, Ariel Jones, head of health care provider solution strategy for Qualtrics XM, addresses inequalities in health care — and how technology, specifical experience management tech, can help bridge the gap.

"As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe," she writes. Read more.

Lawson Gow, co-founder of Pokatok

A new sports festival is headed to Houston next year. Photo courtesy of Pokatok

Pokatok, the recently announced, four-day sports festival is slated to take place April 4-7, 2024.

“Pokatok will not only be the largest gathering of the entire sports tech ecosystem, it will also be a true fan festival for sports enthusiasts,” says Gow in the news release. “Everyone speaks the language of sport, it’s an incredibly powerful unifier of our society, and this festival will bring together people from around the world to experience hundreds of events revolving around the new and the next in sport.”

The festival, which has secured support from Houston First, the Greater Houston Partnership, and the Harris County Houston Sports Authority to put on the event, will feature two tracks — one focused on sports innovation and the other surrounding a fan experience. Pokatok X will include an expo and showcase focused on sports innovation, bringing together startups, investors, accelerators, athletes, and industry experts to dive into sports tech. Read more.

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe. Photo via Getty Images

Houston expert: How technology can be used to bridge the health equity gap

guest column

Progressively over the last decade, the health care industry has become increasingly aware of the role that social determinants of health play in the health outcomes of patients.

Social determinants of health, or SDOH, are the conditions in which people are born, grow, live, work, and age, and they have a significant impact on a person's health and well-being. Examples of SDOH include income, education level, housing, and access to healthy food.

One of the key challenges facing health care organizations and providers is how to address health equity gaps, which are the differences in health outcomes between different populations. Health equity gaps are often caused by social determinants of health, and they can be particularly pronounced among vulnerable populations such as low-income communities, racial and ethnic minorities, and those living in rural areas.

Experience management technology has emerged as a powerful tool for addressing these equity gaps. This technology uses feedback, behaviors, and other relevant SDOH data in order to understand the unique needs of different populations and develop targeted interventions to improve their health outcomes.

One of the key ways that experience management technology can help decrease health equity gaps is by segmenting populations by social determinants of health. By collecting data on patients' demographics, such as their age, race, income, and education level, health care organizations can gain a better understanding of the SDOH that are most relevant to each population. This information can be used to develop personalized actions that address the specific needs of each population, rather than relying on a one-size-fits-all approach.

For example, health care organizations could use experience management technology to gather feedback from patients on their access to healthy food. By segmenting the patient population by zip code, health care organizations could identify patients in rural areas who do not have easy access to quality care facilities and providers. These patients could then be targeted with interventions such as transportation assistance programs or care coordination programs, which could help address their specific needs.

In addition to segmenting populations by social determinants of health, experience management technology can also help health care organizations gather insights into patient behaviors. By integrating data on patients' health behaviors, such as adherence to treatment or missed appointments, health care organizations can develop targeted interventions that encourage healthy behaviors.

For example, health care providers could use experience management technology to collect data on patients' treatment habits. Patients who report low adherence to treatment could be targeted with interventions such as treatment education programs or care coaching, which could help them develop healthier habits over time.

Finally, experience management technology can help health care organizations gain insight into their patient’s end to end journey. By integrating data from multiple sources, such as electronic health records, patient feedback, and social determinants of health data, health care organizations can develop a more comprehensive understanding of patients' health needs and brand expectations. This unified illustration allows health care organizations to improve business outcomes such as lower readmission rates, and create loyal patients that will refer their friends and family in the most important and sensitive moments in their lives.

In conclusion, experience management technology has emerged as a powerful tool for addressing health equity gaps by segmenting populations by social determinants of health, understanding and acting on their unique needs through feedback, behaviors, and dynamic integrations. By leveraging this technology, health care organizations can develop unique solutions that improve the health outcomes of vulnerable populations, such as low-income communities, racial and ethnic minorities, and those living in rural areas.

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe.

------

Ariel Jones is the head of health care provider solution strategy for Qualtrics XM, an American Experience Management company providing software solutions for customer and employee experience.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.